Sagimet Biosciences (SGMT) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

12 Health Care Stocks Moving In Monday's Pre-Market Session
BenzingaDec 16 16:05 ET
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
BenzingaDec 16 06:37 ET
Analysts Offer Insights on Healthcare Companies: Chromadex (CDXC) and Sagimet Biosciences, Inc. Class A (SGMT)
TipRanksDec 8 03:40 ET · Ratings
Sagimet Started at Outperform by Oppenheimer, MASH Drug Cited
Seeking AlphaDec 6 13:56 ET
Sagimet Biosciences Price Target Announced at $30.00/Share by Oppenheimer
Dow JonesDec 6 07:27 ET · Ratings
Oppenheimer Initiates Coverage On Sagimet Biosciences With Outperform Rating, Announces Price Target of $30
BenzingaDec 6 07:16 ET · Ratings

Comments

Jaguar8

Nov 18 09:47

NEWS PM

$Sagimet Biosciences (SGMT.US)$
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
Sagimet Biosciences presented Phase 2b data for denifanstat, its fatty acid synthase (FASN) inhibitor, at AASLD 2024. The FASCINATE-2 trial showed significant improvement in liver fibrosis in high-risk MASH patients, particularly in the F3 population where 49% of denifanstat-treated patients showed improvement versus 13% for placebo. AI-ba...

5

Jaguar8

Nov 12 05:31

NEWS

$Sagimet Biosciences (SGMT.US)$
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
Ascletis Pharma has completed enrollment of 480 patients in its Phase III clinical trial of ASC40 (denifanstat), a once-daily oral tablet for treating moderate to severe acne. The randomized, double-blind, placebo-controlled trial began on January 24, 2024, with patients divided equally between treatment and placebo groups. The study will evalua...

Trytosaveabit

Oct 29 06:04

Update

$Sagimet Biosciences (SGMT.US)$ Reuters· 3 mins ago
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions With FDA on the Development of Denifanstat for Mash; Phase 3 Program Initiation Expected by End of 2024

Jaguar8

Oct 11 06:04

NEWS

$Sagimet Biosciences (SGMT.US)$
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
Sagimet Biosciences Inc. (Nasdaq: SGMT) announced the publication of results from their Phase 2b FASCINATE-2 clinical trial of denifanstat in The Lancet Gastroenterology & Hepatology. The trial, conducted on patients with biopsy-confirmed metabolic-dysfunction associated steatohep...

SGMT Sagimet Biosciences

Trade Overview

Capital Trend

News

Comments